content: SECURITIES AND EXCHANGE COMMISSION
  
                               WASHINGTON, D.C. 20549
  
  
                  -------------------------------------------------
  
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
                       PURSUANT TO SECTION 13 OR 15(D) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
          Date of report (Date of earliest event reported): August 1, 2003
                                                            --------------
  
                                 CYTOGEN CORPORATION
               ------------------------------------------------------
                 (Exact Name of Registrant as Specified in Charter)
  
             Delaware                    000-14879                  222322400
  ----------------------------   ------------------------      -------------------
  (State or Other Jurisdiction   (Commission File Number)       (I.R.S. Employer
        of Incorporation)                                      Identification No.)
  
  650 College Road East, CN 5308, Suite 3100, Princeton, NJ                08540
  ---------------------------------------------------------             ----------
       (Address of Principal Executive Offices)                         (Zip Code)
  
         Registrant's telephone number, including area code: (609) 750-8200
                                                             --------------
  
  
  
  <PAGE>
  
  
  ITEM 5.     OTHER EVENTS AND REQUIRED FD DISCLOSURE.
  
           On August 1, 2003, Cytogen  Corporation (the "Company")  announced that
  the Company  completed  the  reacquisition  of  marketing  rights held by Berlex
  Laboratories,  a  U.S.  affiliate  of  Schering  AG,  Germany,  to  QUADRAMET(R)
  (Samarium  Sm 153  Lexidronam)  in North and Latin  America,  in exchange for an
  upfront payment of $8 million and royalties based on future sales.  QUADRAMET is
  a skeletal targeting therapeutic  radiopharmaceutical for the relief of pain due
  to bone metastases  arising from prostate,  breast,  multiple  myeloma and other
  types of cancer.
  
           Such  press  release  is  attached   hereto  as  Exhibit  99.1  and  is
  incorporated  herein by  reference.  The  foregoing  description  of such  press
  release is qualified in its entirety by reference to such document.
  
  
  ITEM 7.     FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
  
           (c) Exhibits.
  
                 Exhibit No.    Description
                 -----------    -----------
                    99.1        Press release of the Company dated August 1, 2003.
  
  
  
  <PAGE>
  
  
  
                                     SIGNATURES
  
  
  
           Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
  the  Registrant  has duly caused this current report on Form 8-K to be signed on
  its behalf by the undersigned hereunto duly authorized.
  
                                          CYTOGEN CORPORATION
  
  
                                          By:   /s/ Michael D. Becker
                                                ----------------------------------
                                                Michael D. Becker
                                                President and Chief Executive
                                                Officer
  
  Dated:   August 1, 2003
  
  
  
  <PAGE>
  
  
                                    EXHIBIT INDEX
  
  
                 Exhibit No.    Description
                 -----------    -----------
                    99.1        Press release of the Company dated August 1, 2003.
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "form8k080103.txt", "description": "FORM 8-K DATED AUGUST 1, 2003", "secsgml_size_bytes": 3502}]
metadata_filer: {"company-data": {"conformed-name": "CYTOGEN CORP", "cik": "0000725058", "assigned-sic": "2835", "irs-number": "222322400", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-14879", "film-number": "03816366"}, "business-address": {"street1": "600 COLLEGE RD EAST CN 5308", "city": "PRINCETON", "state": "NJ", "zip": "08540", "phone": "6099878200"}, "mail-address": {"street1": "600 COLLEGE RD EAST CN 5308", "street2": "600 COLLEGE RD EAST CN 5308", "city": "PRINCETON", "state": "NJ", "zip": "08540"}}
text: SECURITIES AND EXCHANGE COMMISSION
  
                               WASHINGTON, D.C. 20549
  
                  -------------------------------------------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
                       PURSUANT TO SECTION 13 OR 15(D) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
          Date of report (Date of earliest event reported): August 1, 2003
                                                            --------------
  
                                 CYTOGEN CORPORATION
               ------------------------------------------------------
                 (Exact Name of Registrant as Specified in Charter)
  
             Delaware                    000-14879                  222322400
  ----------------------------   ------------------------      -------------------
  (State or Other Jurisdiction   (Commission File Number)       (I.R.S. Employer
        of Incorporation)                                      Identification No.)
  
  650 College Road East, CN 5308, Suite 3100, Princeton, NJ                08540
  ---------------------------------------------------------             ----------
       (Address of Principal Executive Offices)                         (Zip Code)
  
         Registrant's telephone number, including area code: (609) 750-8200
                                                             --------------
  ITEM 5.     OTHER EVENTS AND REQUIRED FD DISCLOSURE.
  
           On August 1, 2003, Cytogen  Corporation (the "Company")  announced that
  the Company  completed  the  reacquisition  of  marketing  rights held by Berlex
  Laboratories,  a  U.S.  affiliate  of  Schering  AG,  Germany,  to  QUADRAMET(R)
  (Samarium  Sm 153  Lexidronam)  in North and Latin  America,  in exchange for an
  upfront payment of $8 million and royalties based on future sales.  QUADRAMET is
  a skeletal targeting therapeutic  radiopharmaceutical for the relief of pain due
  to bone metastases  arising from prostate,  breast,  multiple  myeloma and other
  types of cancer.
  
           Such  press  release  is  attached   hereto  as  Exhibit  99.1  and  is
  incorporated  herein by  reference.  The  foregoing  description  of such  press
  release is qualified in its entirety by reference to such document.
  
  ITEM 7.     FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
  
           (c) Exhibits.
  
                 Exhibit No.    Description
                 -----------    -----------
                    99.1        Press release of the Company dated August 1, 2003.
  SIGNATURES
  
           Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
  the  Registrant  has duly caused this current report on Form 8-K to be signed on
  its behalf by the undersigned hereunto duly authorized.
  
                                          CYTOGEN CORPORATION
  
                                          By:   /s/ Michael D. Becker
                                                ----------------------------------
                                                Michael D. Becker
                                                President and Chief Executive
                                                Officer
  
  Dated:   August 1, 2003
  EXHIBIT INDEX
  
                 Exhibit No.    Description
                 -----------    -----------
                    99.1        Press release of the Company dated August 1, 2003.